JUNE 2024LIFE SCIENCES REVIEW6Immuno-oncology therapy has ushered in a new era of cancer treatment by harnessing the body's own defenses to combat cancer cells and has already proven effective. From immune-boosting drugs that amplify the body's defenses to monoclonal antibodies that precisely target specific cancer-related proteins, cancer immunotherapy is one where innovation knows no bounds. Among the key trends in cancer treatment, immune checkpoint inhibitor therapies have emerged as a game-changer. These therapies operate by unleashing the power of the body's own immune system to overcome tumor-induced suppression and effectively target cancer cells, offering a novel approach that complements traditional treatments like chemotherapy and radiation.Another significant advancement is Bispecific antibodies, which represent a major development in immunotherapy. These engineered antibodies can simultaneously bind two different targets, such as a tumor cell and an immune cell, facilitating a more accurate and effective immune response against cancer.Driven by these trends, the global cancer immunotherapy market size is projected to hit around $280.11 billion by 2033, growing at a CAGR of 8.34 percent.This edition of the Life Sciences Review Europe offers insights into the latest developments in the Immuno-oncology space and how companies are aligning with these trends. The magazine features a thought-provoking article from Sophie Toya, MD, Associate Director of Clinical Development at Dompé. She highlights the importance of neutrophil extracellular traps (NETs) in acute respiratory distress syndrome (ARDS) pathogenesis and the need for better NET detection methods to improve patient outcomes. Additionally, an article by Clement Lim, Director, Head of Early Cancer Detection, Scientific & Medical Affairs at Mirxes, informs us about the remarkable progress and future potential of immunotherapy in revolutionising cancer treatment while highlighting the need to address current challenges in ensuring unbiased access for all patients. In this edition of Life Sciences Review Europe, we also bring to you the top service providers in cancer immunotherapy research and development. A noteworthy story is that of ChemoMetec. This well-established company offers precise and reliable automated cell counting and analysis instruments. By leveraging its expertise and advanced solutions, it caters to various industry needs, particularly in the cell and gene therapy field.In this edition featuring the top cancer immunotherapy solutions providers in Europe 2024, we hope you find the right partner to meet your organisation's needs.Let us know your thoughts!EDITORIALExploring the Frontiers of Cancer ImmunotherapyCopyright © 2024 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasGilbert HooverAncel CastelinoDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsJUNE - 03 - 2024, Vol 05, Issue - 12 ( ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com VisualizersHenry SmithVictor Cruz Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com
< Page 5 | Page 7 >